Rituximab-induced serum sickness in multiple sclerosis patients.
Mult Scler Relat Disord
; 36: 101402, 2019 Nov.
Article
en En
| MEDLINE
| ID: mdl-31542710
ABSTRACT
Rituximab is a chimeric anti-CD20 monoclonal antibody that is an effective therapy for multiple sclerosis. Rituximab has been associated with the development of serum sickness (type III hypersensitivity) characterized by arthralgia, fever, and rash during the treatment of other conditions, such as rheumatoid arthritis. Here we describe serum sickness associated with rituximab in multiple sclerosis patients and discuss both the management of serum sickness itself and implications for utilizing alternative anti-CD20 monoclonal antibodies for disease management in this patient population.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Enfermedad del Suero
/
Rituximab
/
Factores Inmunológicos
/
Esclerosis Múltiple
Límite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
Mult Scler Relat Disord
Año:
2019
Tipo del documento:
Article